Key Highlights
- Shares rose 22.73% in pre-market trading to $38.06, up from a prior close of $31.01
- Second quarter Revenue of $64.1 million beat the $56.6 million estimate by 13.15%, up 48% year-over-year
- Adjusted loss per share of $0.07 beat the $0.14 estimate expected
- Raised full-year 2026 revenue guidance to $246 million to $250 million, from a prior $228 million to $232 million
- 52-week range stands at $20.13 to $41.22, with a market Capitalization of $2.67 billion
Shares Surge on Strong Quarter and Raised Outlook
HeartFlow (NASDAQ:HTFL) shares rose 22.73% in pre-market trading to $38.06, building on Wednesday's 3.89% regular-session gain, after the company reported second quarter 2026 results that topped expectations across the board. Revenue reached $64.1 million, up 48% year-over-year, beating the $56.6 million consensus estimate by 13.15% and marking the fastest growth rate in eight quarters, while adjusted loss per share narrowed to $0.07, well ahead of the $0.14 loss expected.
Management raised full-year 2026 guidance, with total revenue now expected between $246 million and $250 million, representing 40% to 42% growth, up from a prior outlook of $228 million to $232 million. The company also raised its plaque revenue outlook to $29 million to $31 million and its plaque activated accounts guidance to approximately 1,250, while non-GAAP gross Margin guidance was raised to approximately 82%.
What HeartFlow Does
HeartFlow is a commercial-stage medical technology company specializing in non-invasive solutions for the diagnosis and management of coronary artery disease. Its proprietary HeartFlow Platform leverages artificial intelligence and advanced computational fluid dynamics to transform a single coronary computed tomography angiography scan into a personalized 3D model of a patient's heart, delivering insights into blood flow, stenosis, and plaque composition. Founded in 2007 and headquartered in Mountain View and San Francisco, California, the company serves customers across the United States, United Kingdom, Japan, and Europe.
Growth Drivers and Expansion Plans
The quarter's growth was driven by accelerating plaque adoption, durable FFR-CT utilization, strong new account additions, and continued expansion of the company's core CCTA market. Innovation progress remained on schedule, with Plaque Staging launched in July 2026 and Plaque Tracker, an autonomous processing initiative, on track for a 2027 launch to support the company's mid-term goal of an 85% gross margin. The company also outlined a major total addressable market expansion strategy targeting the asymptomatic patient population, aiming to grow its total addressable market from approximately $6 billion to $11 billion through three randomized controlled trials launching over the next three quarters across coronary calcium, prior myocardial infarction and peripheral artery disease, and prior plaque patient populations.
Improved Financial Efficiency Reinforces the Growth Story
Financial metrics showed meaningful efficiency gains, with non-GAAP operating loss narrowing to $7.9 million from $11.5 million a year earlier and non-GAAP net loss improving to $5.8 million, or $0.07 per share, from $17.6 million, or $2.79 per share. The company ended the quarter with $246.8 million in cash and reaffirmed guidance for Cash Flow profitability by mid-2028. The results and raised outlook reinforce the bullish analyst narrative around the stock, which already carried a consensus Strong Buy rating heading into the print.
Where Things Stand
HeartFlow's pre-market surge reflects a quarter that beat expectations on nearly every metric while meaningfully raising the growth trajectory for the remainder of 2026. With reimbursed technology access targeted before 2030 and a clear pathway to cash flow profitability by mid-2028, the company's expansion into the larger asymptomatic patient market will likely be the key long-term storyline for investors to track alongside continued execution on its core CCTA and plaque businesses.






Please wait processing your request...